[177Lu]Lu-PSMA-617治疗伴大脑和小脑转移的转移性去势抵抗性前列腺癌
回顾性分析2022年3月至2024年4月接受[177Lu]Lu-PSMA-617治疗的589例mCRPC患者,其中12例(2%)伴中枢神经系统转移。从首次给药起中位总生存4.5个月,8例既往中枢神经系统转移患者中3例(37.5%)病灶完全或近完全缓解,4例治疗后新诊断患者中3例(75%)临床快速恶化。无患者完成全部6个周期。
要点
- 589例接受[177Lu]Lu-PSMA-617治疗的mCRPC患者中12例(2%)伴中枢神经系统转移。
- 从首次RLT给药起中位总生存4.5个月(范围1.1-29.87个月)。
- 既往中枢神经系统转移8例中3例(37.5%)影像学完全或近完全缓解。
核心结论
- 作者认为伴中枢神经系统转移的mCRPC患者(无论治疗前或治疗后诊断)预后差,RLT开始后中位生存4.5个月。
- 尽管25%的患者观察到中枢神经系统病灶完全或近完全影像学缓解,仅2例患者完成超过3个周期治疗。
- 鉴于样本量小,作者提出需要更大规模的多中心研究来验证这些发现。
研究设计与样本
- 回顾性分析2022年3月至2024年4月期间接受[177Lu]Lu-PSMA-617首次剂量的mCRPC患者的临床与影像资料。
- 纳入经专用神经影像学放射学确认至少一个脑实质中枢神经系统转移灶的患者,有无组织病理学确认均可。
- 中枢神经系统转移定义为累及大脑、小脑或脊髓的转移灶;排除仅有硬脑膜转移而无脑实质中枢神经系统病变的mCRPC患者。
- 589例接受[177Lu]Lu-PSMA-617治疗的mCRPC患者中12例(2%,12/589)伴中枢神经系统转移。
- 12例中8例(67%,8/12)为既往存在中枢神经系统病灶,其余4例(33%,4/12)在开始RLT后诊断中枢神经系统转移;患者未同时接受其他全身或局部治疗。
主要发现
- 平均随访期5.7±6.9个月;从RLT首次给药起中位总生存4.5个月(范围1.1-29.87个月)。
- 8例既往中枢神经系统转移患者中,RLT后3例(37.5%,3/8)中枢神经系统病灶完全或近完全缓解,2例(25%,2/8)呈混合缓解,3例(37.5%,3/8)出现中枢神经系统疾病进展。
- 4例开始治疗后诊断中枢神经系统转移的患者中,3例(75%,3/4)临床快速恶化需紧急干预,其余1例(25%,1/4)对治疗反应良好且未出现新发或加重的神经系统症状。
- 无患者能完成全部6个周期RLT,停药主要因整体疾病进展或感染相关并发症。
局限性
- 原文为回顾性研究。
- 样本量小(12例中枢神经系统转移患者)。
- 作者结论指出需要更大规模的多中心研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) metastases in prostate cancer are rare but pose a significant treatment challenge and are linked to poor prognosis. Data on the outcomes of this specific patient subgroup treated with radioligand therapy (RLT) remain scarce. In this study, we aim to leverage real-world clinical data to evaluate the outcomes of RLT with [177Lu] Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) and CNS metastases. METHODS: Clinical and imaging data of patients who received their initial dose of [177Lu] Lu-PSMA-617 between March 2022 and April 2024 were retrospectively reviewed. All patients who were known to have at least one parenchymal CNS metastasis confirmed radiologically through dedicated neuroimaging, with or without histopathological confirmation, were included in the study. Central nervous system metastases (CNS) were defined as metastatic lesions involving the cerebrum, cerebellum, or spinal cord. The mCRPC patients with dural metastases but without parenchymal CNS disease were excluded. RESULTS: A total of 589 patients underwent RLT with [177Lu] Lu-PSMA-617 for mCRPC, of whom 12 (2%, 12/589) had CNS metastases. Among these, eight patients (67%, 8/12) had pre-existing CNS lesions, while the remaining four patients (33%, 4/12) were diagnosed with CNS metastases after initiating RLT. Patients received no additional systemic or focal therapies concurrently with RLT. The mean follow-up period was 5.7 ± 6.9 months. The median overall survival from the initial dose of RLT was 4.5 months (range: 1.1-29.87 months). Among eight patients with pre-existing CNS metastases, CNS lesions resolved completely or nearly completely in three patients (37.5%, 3/8), while two patients (25%, 2/8) exhibited a mixed response, and three patients (37.5%, 3/8) experienced CNS disease progression following RLT. Among four patients diagnosed with CNS metastases after initiating therapy, three patients (75%, 3/4) experienced a rapid clinical decline necessitating urgent intervention, while the remaining patient (25%, 1/4) responded well to the therapy without developing new or worsening neurological symptoms. None of the patients were able to complete the full six cycles of RLT, with discontinuation mainly due to overall disease progression or infection-related complications. CONCLUSIONS: Our study suggests that patients with CNS metastases, whether diagnosed before or after therapy, exhibited a poor prognosis, with a median survival of 4.5 months after initiation of RLT. Although a complete/near-complete radiologic response in the CNS lesions was observed in 25% of the patients, only two patients were able to complete more than three cycles of therapy. Given the small sample size, larger multicenter studies are needed to validate these findings.
引用
- Belge Bilgin G, Bilgin C, Burkett BJ, et al. [177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases. Eur J Nucl Med Mol Imaging. 2025. PMID: 40689993. doi:10.1007/s00259-025-07447-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。